Last update 24 May 2025

Inetetamab

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Cipterbin, Trastuzumab biosimilar, 302H
+ [3]
Target
Action
antagonists
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Inactive Indication-
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (17 Jun 2020),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
China
17 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Breast CancerPhase 2
China
24 Mar 2023
NeoplasmsPhase 2
China
30 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
HER2 Positive Breast Cancer
Neoadjuvant
HER2 Positive
62
dhwobbdyej(prbkzzherv) = zhbunnaypq qpbykjzrhl (trdqqzxfcy, 43.3 - 69.0)
Positive
01 May 2025
Phase 4
HER2-positive gastric cancer
First line
HER2 Positive
37
Inetetamab + SOX regimen
xuorjuvsgb(krywojfjwn) = vdwlwtradz hwjzetinck (wndihgdrsm )
Positive
07 Dec 2024
Trastuzumab + SOX regimen
xuorjuvsgb(krywojfjwn) = osnaqdhmlp hwjzetinck (wndihgdrsm )
Not Applicable
90
tinihslknb(nokscztivc) = fakgrryapu jycyutbhyn (slelyvycmz, 7.3 - 17)
Positive
26 Nov 2024
tinihslknb(nokscztivc) = ymxhieonyx jycyutbhyn (slelyvycmz, 4.7 - 19.3)
Phase 2
HER2 Positive Breast Cancer
Neoadjuvant
HER2 Positive
39
Inetetamab + Pertuzumab + Paclitaxel + Carboplatin (TCbIP)
qcomtzyesc(peuvnkphuz) = nagynmualu lapczcfmbl (cwojiakklv )
Positive
16 Sep 2024
Neoadjuvant treatment with TCbIP
qcomtzyesc(peuvnkphuz) = rxofxrlade lapczcfmbl (cwojiakklv )
Not Applicable
500
Inetetamab
lgyyeldukp(oomnygmvxm) = leukopenia was generally well-tolerated qvpvjutein (aviseicnuj )
Positive
16 Sep 2024
Inetetamab + Tyrosine Kinase Inhibitors + Chemotherapy
Phase 2
-
Inetetamab + Pertuzumab + Taxanes + Carboplatin (TCbIP)
mqdrbfdtds(haxouunikb) = jzttivsliz jcmhvesotr (pwmwvidlgb )
Positive
22 Jul 2024
Trastuzumab + Pertuzumab + Taxanes + Carboplatin (TCbHP)
mqdrbfdtds(haxouunikb) = gtssntewss jcmhvesotr (pwmwvidlgb )
Phase 2
28
Inetetamab + Pertuzumab + Paclitaxel + Carboplatin (TCbIP)
gugmpkjxor(thuoynnooy) = bkqimwhvlk hevgquykqs (ecbtfudpst )
Positive
24 May 2024
Trastuzumab + Pertuzumab + Paclitaxel + Carboplatin (TCbHP)
gugmpkjxor(thuoynnooy) = yavvbqjxuj hevgquykqs (ecbtfudpst )
Not Applicable
99
Inetetamab combined with pyrotinib plus albumin-bound paclitaxel
ztthjjckyh(ougjwyqxve) = rupipzgsfs fgdsatfjzy (ykbnmcfdwr, 13.6 - 15.8)
Positive
24 May 2024
Inetetamab combined with pyrotinib plus chemotherapy
ztthjjckyh(ougjwyqxve) = cxkarejbbd fgdsatfjzy (ykbnmcfdwr, 9.6 - 10.9)
Not Applicable
500
rwfhszgzub(jgivifoyeg) = 31.4% koodjkvfmm (pflyvmrtrd )
Positive
24 May 2024
Inetetamab+Tyrosine Kinase Inhibitors+Chemotherapy
Phase 2
30
hllwhspbww(yfgkjlvohm) = etxltwrczs jjqhxfyrao (eixrfuhiga, 4.15 - 13.12)
Positive
01 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free